LAD II (OMIM 266265) is a rare autosomal recessive syndrome initially described in Arab children in Israel (1) (2) (3) (4) (5) . The disease is characterized by a set of clinical symptoms that include severe growth and mental retardation, unusual facial appearance, dwarfism, neurologic abnormalities, immunodeficiency with recurrent bacterial infections, leukocytosis (with white blood cell counts ranging from 25,000 to 150,000/mm 3 ), and Bombay blood phenotype (1, 2) . The biochemical hallmark is a lack of expression of fucosylated glycoconjugates, including H-antigen and Lewis antigens such as Lewis X (LeX) and sialyl-Lewis X (SLeX) (1) . The latter molecules are the physiologic ligands for E-and P-selectin, which mediate the initial rolling of neutrophils on the activated endothelium during the recruitment of these cells to the site of inflammation (6 -9) . As a consequence, neutrophils from LAD II patients are unable to interact with selectins and to roll on activated endothelial cells and are impaired in the in vivo chemotaxis in skin-chamber assays (10 -12) .
The widespread severely decreased fucosylation observed in several types of glycoconjugates suggested that the molecular defect of the disease might impair the production or subsequent utilization of GDP-L-fucose rather than the activity of specific fucosyltransferases, which were found to be normal in LAD II patients (13) . Recently, Karsan et al. (4) proposed that the defect in Arab LAD II patients could be localized in the de novo GDP-L-fucose biosynthetic pathway. Indeed, the activities of the two enzymes involved in the de novo biosynthesis, GMD (14 -16) and FX protein (17) , were measured; whereas FX was found to be normal, GMD activity was significantly lower in cell lysates from LAD II patients compared with controls and exhibited kinetic abnormalities (18) . However, no mutation was found in the GMD cDNA isolated from LAD II patients, and GMD protein was present in amounts comparable to control cells, suggesting that the reduced enzymatic activity might be related to an alteration of some regulatory mechanism and not to a genetic defect directly involving this protein (18) . Recently, a child of Turkish origin was described with a clinical phenotype consistent with LAD II syndrome (19) . Cells from this patient display hypofucosylation of cell surface glycoconjugates, with decreased expression of SLeX on neutrophils and reduced binding to E-and P-selectins (19) . Decreased GDP-L-fucose transport into Golgi vesicles was detected in cells derived from this patient (20) .
Despite common symptoms and biochemical abnormalities, differences between the Arab and Turkish patients were observed. The activity of GMD was not altered in the Turkish patient (21) . The Arab LAD II patients and the Turkish child responded differently to replacement therapy with oral fucose: thus, whereas a significant response was observed in the Turkish patient, both as expression of selectin ligands and as improvement of the clinical symptoms (22) , no effects were observed in the two Arab children even after long-term administration of high doses of fucose (5) .
These differences between the Arab and the Turkish patients prompted us to study in an Arab patient the biochemical properties of those processes, downstream of GDP-L-fucose biosynthesis, that result in the fucosylation of membrane glycoconjugates. We observed that GDP-L-fucose transport activity into the Golgi is defective. The kinetic differences underlying GDP-L-fucose transport seem to reasonably account for the outcome of L-fucose replacement therapy, which was successful in the Turkish patient and unsuccessful under the same schedule of treatment with another Arab patient. The biochemical data obtained in the present study suggest that despite the similar clinical phenotype, the Arab and Turkish patients may be affected by variants of LAD II at the biochemical and molecular level. (23) .
METHODS

Materials
Activity of the GDP-L-fucose salvage pathway. Activity of the GDP-L-fucose salvage pathway was analyzed on EBV-cell cytosols. After being washed twice with PBS, cells were lysed in Tris/HCl buffer, pH 8.0, containing protease inhibitors (0.1 g/mL pepstatin, 0.1 g/mL chymostatin, 0.1 g/mL leupeptin, 0.1 g/mL antipapain, and 1 g/mL aprotinin) by use of a Dounce homogenizer. Lysates were then centrifuged at 100,000 ϫ g for 1 h at 4°C. Supernatants were then incubated at 37°C at a final protein concentration of 1 mg/mL in the presence of 100 M [ 3 H]-fucose, 5 mM GTP, 5 mM ATP, 20 mM MgCl 2 , and 10 U/mL inorganic pyrophosphatase. At different time points, aliquots were withdrawn, extracted, and analyzed for GDP-L-fucose formation by HPLC, as previously described (17) . After labeling, cells were washed three times with ice-cold PBS and resuspended in 400 L of ethanol 70%. After 15 min on ice, samples were centrifuged for 5 min at 15,000 ϫ g, and the supernatants were subjected to descending paper chromatography (Whatmann 1MM) in ethanol/ammonium acetate (1 M, pH 7.5) (6:4). The paper strips were cut into 1-cm pieces and shaken for 2 h at room temperature in 1.5 mL of water before addition of 18 mL of scintillation liquid and counting. Standard 3 H-labeled GDP-L-fucose and fucose were chromatographed in parallel and used to identify the corresponding compounds in samples. Preparation of Golgi-enriched membrane fraction and transport assay of sugar nucleotides. Golgi-derived vesicles were prepared by a modification of procedures described previously (24) ; all procedures were performed at 4°C. For each preparation, 2.5 ϫ 10 8 cells were used; cells were pelleted by centrifugation at 500 ϫ g for 5 min, washed twice with ice-cold PBS, resuspended in 3 vol of STM buffer (10 mM Tris-HCl pH 7.5, 1 mM MgCl 2 , 8.5% sucrose) containing protease inhibitors, and disrupted with a tight-fitting Dounce homogenizer. Whole cells and nuclei were removed by centrifugation at 1000 ϫ g for 10 min. The supernatant was overlaid onto a cushion of 10 mM Tris-HCl pH 7.5, 1 mM MgCl 2 , and 44.5% sucrose and was then centrifuged for 1 h at 100,000 ϫ g at 4°C in a SW41 rotor (Beckman Instruments, Inc., Palo Alto, CA, U.S.A.). Golgi-enriched vesicles were collected at the 8.5-44.5% sucrose interface, centrifuged again at 100,000 ϫ g for 30 min, and resuspended in a small volume of STM buffer. The Golgi marker enzyme sialyltransferase was assayed as described previously (25) by using asialofetuin as acceptor.
Transport assay of nucleotide sugars into Golgi-enriched vesicles was performed as described previously (26, 27) with some modifications. Assays were performed in 0.2 mL final volume using 100 g of Golgi vesicles protein; the reaction 538 mixture also contained 0.5 mM 2,3-dimercaptopropanol, an inhibitor of nucleotide pyrophosphatase (28) . The rate of GDP-L-fucose uptake at different concentrations was determined maintaining the amount of radioactive nucleotide sugar constant, whereas unlabeled GDP-L-fucose ranged between 0.125 and 40 M. The other nucleotide sugars were assessed at a concentration of 20 M. Nonspecific adsorption of the nucleotide sugars and contamination in the extravesicular space were found to be minimal in the experimental conditions used. After 5 min at 30°C, reactions were stopped by placing samples on ice and by addition of 0.25 mL of ice-cold STM buffer. Reaction mixtures were immediately spun at 100,000 ϫ g for 15 min. Pellets were washed twice with 0.5 mL of ice-cold STM buffer and dissolved in 0.6 mL of NaOH 1 N; after neutralization with 0.2 mL of 4 N HCl, samples were counted by scintillation spectrometry.
Fucose administration to an LAD II patient. A male infant of Arab origin was diagnosed as suffering from LAD II at the age of 2 wk. The parents are first-degree cousins and came from the same geographic area in Israel as the other LAD II families previously described. He received a previous oral treatment with fucose from the age of 4 wk for 6 mo (starting from 2 g/day and then decreased to 1 g/day after 1 mo of therapy) (5) . For the present study, fucose (500 mg/kg five times a day) was administered orally starting at the age of 11 mo by using the same protocol described by Marquardt et al. (22) . Informed consent was obtained from the parents before the start of therapy, and the protocol was approved by the Institutional Review Board of the Rambam Medical Center. Clinical response to therapy was assessed by blood cell counts, CD15a (SLeX) expression on neutrophils, clinical evaluation of growth and neurologic involvement, and by analysis of P-selectin expression on blood cells by flow cytometry using a P-selectin-IgG conjugate (kindly provided by Dr. Marquardt) (22) .
RESULTS
Fucose replacement therapy in two Arab infants with LAD II failed to improve clinical symptoms and induced no change in neutrophil counts or surface markers (5). To rule out that different protocols of administration account for the differences in response to the treatment, we started fucose therapy in the Arab patient under study by using a protocol identical to that reported by Marquardt et al. (22) , which proved to be useful in the Turkish patient. The child was treated for more than 4 mo without any side effects. Leukocyte count was 35,000 mm 3 before therapy, and no significant change was observed during the entire treatment period (total leukocyte counts ranging from 30,000 to 50,000 mm 3 with neutrophils representing 75 to 80% of the cells). Furthermore, no H antigen on erythrocytes or CD15a on neutrophils were expressed during treatment. Binding of P-selectin-IgG conjugate to neutrophils, a sensitive marker to detect fucose expression on cell surfaces (22) , was not detected in the Arab patient even after 150 d of treatment. We were also unable to observe any change in growth patterns and neuropsychologic parameters.
Fucose metabolism was investigated in EBV-transformed lymphoblasts from an Arab LAD II patient, his parents, and control. As generalized hypofucosylation is a biochemical hallmark of cells derived from LAD II patients (1, 20) , we determined whether fucose incorporation into macromolecules was affected in cells obtained from this patient. EBVtransformed lymphoblasts were grown in the presence of [ 3 H]-fucose, which can be converted to GDP-L- [ 3 H]-fucose by the salvage pathway (29, 30) . As shown in Figure 1, A and B , whereas the amount of radiolabeled fucose bound to acidprecipitable macromolecules was comparable in control, mother, and father, incorporation into macromolecules in patient cells was severely impaired (20% of that observed in the other samples). The decreased incorporation of fucose was specific, because labeling with [ 3 H]-N-acetyl-D-mannosamine, a specific precursor for sialic acid synthesis (31), was similar in control and patient samples (Fig. 1C) . Consistent with these data, no significant differences were observed in the activity of the GDP-L-fucose salvage pathway in the cytosolic fraction of EBV lymphoblasts from control, mother, father, and patient (0.39, 0.44, 0.71, and 0.57 nmol·h -1 ·mg -1 protein, respectively). To determine the relative cytosolic concentrations of GDP-L-fucose, cells were labeled for 72 h with [ 3 H]-fucose until a steady state labeling of the GDP-L-fucose pool was reached. As shown in Figure 2 , GDP-L- [ 3 H]-fucose in patient cells was 60% higher than in control, mother, and father. These results, together with the observation that no decrease in fucosyltransferase activity was observed in the Arab patients (13) , suggest that the mechanism responsible for hypofucosylation observed in patient cells is not the result of decreased cytosolic production of GDP-L-fucose in the cytosol and may likely be upstream of fucosyltransferases, i.e. impaired transport into the Golgi lumen.
To determine directly whether or not GDP-L-fucose transport was compromised in this patient, a Golgi-enriched fraction was obtained from EBV-transformed lymphoblasts, and transport of several nucleotide sugars was measured in vitro. Figure  3A shows that transport of GDP-L-fucose into the Golgi apparatus of patient cells was approximately 30% of that observed for mother, father, and control. Decrease was specific, because transport of CMP-sialic acid (Fig. 3B) , UDP-galactose (Fig.  3C) , and UDP-N-acetyl-galactosamine (Fig. 3D ) was comparable in all samples. These results also demonstrate that the integrity of Golgi vesicles was comparable in every Golgi preparation and that the defect in GDP-L-fucose transport detected in the patient was not a consequence of broken vesicles. Vesicles from all samples were enriched approximately 10-fold in the activity of sialyltransferase over the starting homogenate (data not shown), showing that the preparations were of comparable purity (25) .
The GDP-L-fucose transport activity in all samples was saturable with the presence of only one component in the corresponding saturation curves. For the control Golgi vesicles, an apparent K m determined by nonlinear regression of 9.5 Ϯ 2.5 M and a V max of 56.6 Ϯ 3.3 pmol·min -1 ·mg -1 of protein was obtained (Fig. 4, A and B) . Although Golgi vesicles obtained from EBV lymphoblasts of both father and mother showed kinetic parameters of GDP-L-fucose transport comparable to control vesicles, those derived from the LAD II patient displayed a significant decrease in the V max , which was 18.9 Ϯ 2.8 pmol·min -1 ·mg -1 (Fig. 4) , whereas the K m of patient cells was comparable to those measured in control and parent samples as demonstrated by the double reciprocal plot (Fig.  4B) .
DISCUSSION
LAD II syndrome is a rare autosomal recessive genetic disease initially confined to the Arab population in Israel (1-5). The four Arab patients diagnosed to date are from the same village, and some of the parents are related. Given the restricted geographical area in which these cases were found, it is likely that these patients have a common genetic defect. The recent identification in Germany of an infant of Turkish origin with a clinical presentation consistent with LAD II (19) indicates a broader distribution of the disease and suggests that the real incidence may be underestimated. Our study was motivated by the completely different outcomes of fucose replacement therapy, i.e. successful in the Turkish patient (22) and unsuccessful in Arab patients (five and this study). Indeed, although the main clinical symptoms that identify LAD II syndrome are similar in the Arab and Turkish patients, some differences in the clinical phenotype were observed (1, 2, 5, 19) . Importantly, activity of GMD was reduced in cell lysates from Arab patients (18) , whereas it was normal in the Turkish patient (21) . Taken together, these data would be consistent with different molecular defects in the Turkish and Arab patients.
Our biochemical studies show a decreased expression of 3 H-labeled fucose in macromolecules of EBV-transformed lymphoblasts and demonstrate that this decrease is not correlated with alterations in GDP-L-fucose salvage pathway activity. We have found that GDP-L-fucose transport was specifically impaired in Golgi vesicles from this Arab patient compared with the control and parents, displaying a significant and specific reduction in the V max of the transport activity. GDP-L-fucose transport showed only one saturable component with a K m of approximately 9 M for control, patient, and parents. This result is consistent with the kinetic patterns and apparent K m values previously measured for the rat liver Golgi transport of GDP-L-fucose (27, 32) and of other nucleotide sugars into the Golgi apparatus (33) . A defective import of GDP-L-fucose into Golgi vesicles has also been detected in the Turkish LAD II patient described in Germany (20) . However, the kinetic parameters reported in that study for GDP-L-fucose transport in fibroblast-derived Golgi vesicles for both control and LAD II patient are different compared with our data. That study showed two-component kinetics with an initial saturable component followed by a nonsaturable one. The apparent K m for the saturable component in the control was 0.7 M, whereas the overall affinity of the transporter for GDP-L-fucose in Golgi vesicles from the patient was not estimated and appeared to be decreased in the saturable component compared with the control (20) . It is not clear whether the biphasic patterns observed for GDP-L-fucose transport in the study with the Turkish LAD II cells also occur with other nucleotide sugars. Previous studies by our group using fibroblasts have always shown Michaelis-Menten kinetics (24, 34) . The differences observed in transport characteristics cannot be explained by the different source of Golgi vesicles (EBV lymphoblasts versus fibroblasts). Preliminary data obtained in our laboratory, using Golgi vesicles from both control and LAD II patient fibroblasts, have shown kinetic parameters similar to those observed for EBV cells with an identical K m value (our unpublished results).
Lubke et al. (20) proposed that the biochemical defect in the Turkish patient may be due to an abnormal K m of the GDP-Lfucose transporter, as incubation of the patient fibroblasts with 1 mM fucose but not 1 mM mannose overcame the fucosylation defect (20) . If the ability of exogenous fucose to correct the phenotype relies on increasing the cytosolic concentration of GDP-L-fucose and thereby on overcoming the consequences of an increased K m , as inferred by Lubke et al. (20) , then the failure of the Arab children to respond to fucose replacement therapy is consistent with our observation that the affinity of GDP-L-fucose transport in the Arab patients is comparable to his parents and the control. Addition of 10 mM fucose to EBV lymphoblasts, fibroblasts, and endothelial cells derived also from Arab subjects resulted in the expression of fucosylated epitopes on the cell surface (4). However, we speculate that the effects seen at high concentrations, approximately 50 -100-fold higher than the maximal serum levels detected in vivo after administration of high doses of fucose (5), are not physiologic.
A decrease of GDP-L-fucose availability for the fucosyltransferases within the Golgi lumen explains the generalized reduction of fucose in the different types of glycoconjugates. However, the fact that whereas some fucosylated antigens are absent, cells derived from the patient incorporate low but detectable levels of fucose into macromolecules, indicates that not all fucose-containing glycoconjugates are comparably decreased. This is most likely the consequence of different K m values of fucosyltransferases catalyzing the addition of fucose to selected acceptors under limiting supply of GDP-L-fucose in the lumen of the Golgi apparatus (34) . At the same time, the defective import into the Golgi causes an increased cytosolic concentration of this nucleotide sugar, which may be responsible for the alterations in the kinetic properties of GMD observed in cell lysates from LAD II Arab patients (18) , through feedback inhibition. In fact, GDP-L-fucose has been shown in our laboratory to behave as a potent noncompetitive inhibitor of human recombinant GMD, with a K i of approximately 11 M (16).
Currently, no information is available on either the gene or amino acid sequence of the mammalian GDP-L-fucose transporter. This specific transporter has been purified from rat liver and identified as an 80-kD protein with 39 kD subunits as determined by SDS-PAGE (27) , strongly suggesting a homodimeric structure; this is in agreement with previously published structures for other Golgi transporters (35) . Identification of the human gene encoding for the GDP-L-fucose transporter should eventually clarify whether the defect in LAD II affects the transporter structural gene, its promoter, or other regulatory components of its activity and will also elucidate the molecular mechanisms underlying possible variants of this disease.
